Description

Add as a preferred source on Google

COVAXIN, a COVID-19 vaccine manufactured by Bharat Biotech, received a certificate of Good Manufacturing Practice (GMP) compliance from the authorities of Hungary on August 5, 2021. Bharat Biotech announced the news in a tweet, noting that this is the company's first EUDRAGDMP compliance certificate from European authorities. The National Institute of Pharmacy and Nutrition Hungary approved COVAXIN's GMP for the manufacture of the COVID-19 vaccine.

Click on the image to view the official tweet –

According to an official statement, Bharat Biotech has achieved another significant milestone in innovating and manufacturing vaccines at global quality standards, as well as moving forward in the ongoing fight against the Coronavirus pandemic. It went on to say that Hungary's recognition strengthens the company's commitment to driving world-class innovation and being a leader in vaccine research and development.

The EudraGMDP now includes a certificate of Good Manufacturing Practice (GMP). It is the European Community's database of manufacturing authorizations and certificates of the good manufacturing practice. Bharat Biotech also intends on submitting the documentation for the Emergency Use Authorization (EUA) in several additional countries worldwide.

About Bharat Biotech’s COVAXIN

Meanwhile, according to a study conducted by the Indian Council of Medical Research-National Institute of Virology, COVAXIN from Bharat Biotech showed less reduction in ‘neutralizing activity' when compared to the Delta and Delta AY.1 (Delta Plus) variants in those who had received full COVID-19 vaccination. This means that COVAXIN vaccine recipients will be protected against the current variants Delta, Delta AY.1, and B.1.6.17.3.

COVAXIN is a Coronavirus vaccine developed in collaboration with the Indian Council of Medical Research by Bharat Biotech. It is a virus-based vaccine that has been inactivated. The vaccine was granted emergency use authorization by India's drug regulatory body in January 2021. After Serum Institute and Pfizer, it was the third vaccine to apply for approval.

For more Updates and Information - Click here 

For access to more than 10,000 Colleges - Click here

For Latest Sarkari Jobs - Click here

For Comprehensive Preparation of Competitive Exams - Click here

For School Studies and Exams Preparation across Eight Boards - Click here